Heart failure & cardiomyopathies
Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure
Authors' conclusion
The present study suggests that serum AAT is a reliable biomarker for CHF in a Chinese population.
Study context
- Population
- Patients with ischaemic or non-ischaemic heart disease with or without chronic heart failure (CHF); Chinese population3 validation cohorts
- Comparison
- Serum AAT in CHF vs no CHF
- Outcome
- Serum AAT concentration, IHD vs IHF
Methodological detailsserum proteomics (iTRAQ), three independent validation cohorts
- Serum proteomics (iTRAQ)
- Three independent validation cohorts
Performance
As reported in the abstract
- Ischaemic heart failure (IHF) vs ischaemic heart disease (IHD): P < 0.001
- IHF vs IHD: P < 0.001
- Cohort A: 223 IHD, 321 IHF; cohort B: 817 IHD, 1139 IHF; cohort C: 559 non-ischaemic (316 CHF, 243 no CHF)
Further findings
Independent association of AAT with CHF (multivariate logistic regression)
| OR (95% CI) | P value | ||
|---|---|---|---|
| AATCohort A · adjusted for confounders | 3.14 (1.667–5.90) | P < 0.001 | |
| AATCohort B · adjusted for confounders | 4.10 (2.97–5.65) | P < 0.001 | |
| AATCohort C · adjusted for confounders | 1.86 (1.02–3.38) | P = 0.043 | |
| 0.20.5125Odds ratio (log scale) |
Discrimination of IHF vs stable IHD (ROC)
- AUC, cohort A
- 0.70 (95% CI 0.66 to 0.74, P < 0.001)
- AUC, cohort B
- 0.74 (95% CI 0.72 to 0.76, P < 0.001)
Correlation of AAT with LVEF
- AAT negatively correlated with LVEF
- r = −0.261, P < 0.001
Original publication
Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure. ESC Heart Fail. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →